Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + RT in Chinese SCCHN
NCT01012258Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2009
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Merck KGaA. Started Feb 2009; status: completed.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01012258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012258.